Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
About this trial
Large (≥20mm) colorectal polyps often harbor areas of advanced neoplasia, making them immediate colorectal cancer (CRC) precursors. Such polyps have to be completely removed to prevent CRC and to avoid surgery and/or adjuvant therapy. The laterally spreading lesions (LSLs) are removed via endoscopic mucosal resection (EMR). However, recurrence is common. New techniques for LSL resection (hybrid argon plasma coagulation (h-APC) margin and base ablation) have shown a reduction in recurrence following the interventions.
We hypothesize that performing hybrid argon plasma coagulation (h-APC) margin and base ablation during EMR of large (≥20mm) colorectal LSLs will lead to lower rates of lesion recurrence compared to Snare tip soft coagulation (STSC) margin ablation.
Eligibility criteria
Qualifiers
adult ≥18 years old
patients undergoing EMR for a large (≥20mm) colorectal LSL
patients providing written and informed consent for study participation.
Disqualifiers
inflammatory bowel disease;
non-elective colonoscopy;
poor general health (American Society of Anesthesiologists classification >III);
coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets <50 x 109/L);
Trial design
Treatments tested in this trial
- Hybrid Argon Plasma Coagulation (h-APC)
- Snare tip soft coagulation (STSC)
Treatment groups
892 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov